161 related articles for article (PubMed ID: 34893942)
1. Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma.
Hess B; Townsend W; Ai W; Stathis A; Solh M; Alderuccio JP; Ungar D; Liao S; Liao L; Khouri L; Zhang X; Boni J
AAPS J; 2021 Dec; 24(1):11. PubMed ID: 34893942
[TBL] [Abstract][Full Text] [Related]
2. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
[TBL] [Abstract][Full Text] [Related]
3. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.
Xu B
Eur J Clin Pharmacol; 2022 May; 78(5):707-719. PubMed ID: 35061047
[TBL] [Abstract][Full Text] [Related]
4. Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
Ahmed N; Hamadani M
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1313-1320. PubMed ID: 34597242
[TBL] [Abstract][Full Text] [Related]
5. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M; Heffner LT; Ungar D; Wang L; Boni J; Havenith K; Qin Y; Kahl BS
Blood; 2021 May; 137(19):2634-2645. PubMed ID: 33211842
[TBL] [Abstract][Full Text] [Related]
6. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
[TBL] [Abstract][Full Text] [Related]
7. Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.
Goparaju K; Caimi PF
Expert Opin Biol Ther; 2021 Nov; 21(11):1373-1381. PubMed ID: 34505550
[TBL] [Abstract][Full Text] [Related]
8. Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Spira A; Zhou X; Chen L; Gnanasakthy A; Wang L; Ungar D; Curiel R; Liao L; Radford J; Kahl B
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):158-168. PubMed ID: 34690090
[TBL] [Abstract][Full Text] [Related]
9. Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunction.
Baek GT; Huang IJ; Gopal AK
Cancer; 2023 Aug; 129(15):2279-2283. PubMed ID: 37208793
[TBL] [Abstract][Full Text] [Related]
10. Loncastuximab tesirine for diffuse large B-cell lymphoma.
Zurko J; Hamadani M
Drugs Today (Barc); 2021 Dec; 57(12):733-743. PubMed ID: 34909802
[TBL] [Abstract][Full Text] [Related]
11. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
Jain N; Stock W; Zeidan A; Atallah E; McCloskey J; Heffner L; Tomlinson B; Bhatnagar B; Feingold J; Ungar D; Chao G; Zhang X; Qin Y; Havenith K; Kantarjian H; Wieduwilt MJ
Blood Adv; 2020 Feb; 4(3):449-457. PubMed ID: 32012214
[TBL] [Abstract][Full Text] [Related]
12. Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Hamadani M; Chen L; Song Y; Xu MK; Liao L; Caimi PF; Carlo-Stella C
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e738-e744. PubMed ID: 35513980
[TBL] [Abstract][Full Text] [Related]
13. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
Caimi PF; Ai WZ; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Wang Y; Qin Y; Wang L; Xu ZC; Carlo-Stella C
Haematologica; 2024 Apr; 109(4):1184-1193. PubMed ID: 37646659
[TBL] [Abstract][Full Text] [Related]
14. The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma.
Calabretta E; Hamadani M; Zinzani PL; Caimi P; Carlo-Stella C
Blood; 2022 Jul; 140(4):303-308. PubMed ID: 35580172
[TBL] [Abstract][Full Text] [Related]
15. Loncastuximab Tesirine: First Approval.
Lee A
Drugs; 2021 Jul; 81(10):1229-1233. PubMed ID: 34143407
[TBL] [Abstract][Full Text] [Related]
16. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data.
Furqan F; Hamadani M
Ther Adv Hematol; 2022; 13():20406207221087511. PubMed ID: 35340719
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
Zinzani PL; Minotti G
J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma.
Toukam M; Wuerthner J; Havenith K; Hamadani M; Caimi PF; Kopotsha T; Cruz HG; Boni JP
Cancer Chemother Pharmacol; 2023 Jan; 91(1):13-24. PubMed ID: 36333464
[TBL] [Abstract][Full Text] [Related]
19. Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Toukam M; Boni JP; Hamadani M; Caimi PF; Cruz HG; Wuerthner J
Cancer Chemother Pharmacol; 2023 Jan; 91(1):1-12. PubMed ID: 36333463
[TBL] [Abstract][Full Text] [Related]
20. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
